Literature DB >> 26140231

Kick-starting the cancer-immunity cycle by targeting CD40.

P Ellmark1, S M Mangsbo2, C Furebring3, T H Tötterman2, P Norlén3.   

Abstract

Stimulation of CD40 on dendritic cells to expand and activate tumor-specific T cells and generate anticancer immunity is an attractive therapeutic approach. Since CD40 agonists exert their effects upstream of checkpoint inhibitors, including PD-1 or PD-L1 antagonists, they are ideal candidates for combination regimens.

Entities:  

Keywords:  CD40; PD-1; agonistic antibody; immunooncology

Year:  2015        PMID： 26140231      PMCID： PMC4485842          DOI： 10.1080/2162402X.2015.1011484

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.

Authors:  Sara M Mangsbo; Sissela Broos; Erika Fletcher; Niina Veitonmäki; Christina Furebring; Eva Dahlén; Per Norlén; Malin Lindstedt; Thomas H Tötterman; Peter Ellmark
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

2.  Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment.

Authors:  Alfred Zippelius; Jens Schreiner; Petra Herzig; Philipp Müller
Journal:  Cancer Immunol Res       Date:  2015-01-26       Impact factor: 11.151

3.  Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.

Authors:  Marieke F Fransen; Marjolein Sluijter; Hans Morreau; Ramon Arens; Cornelis J M Melief
Journal:  Clin Cancer Res       Date:  2011-03-09       Impact factor: 12.531

4.  Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.

Authors:  Linda C Sandin; Anna Orlova; Erika Gustafsson; Peter Ellmark; Vladimir Tolmachev; Thomas H Tötterman; Sara M Mangsbo
Journal:  Cancer Immunol Res       Date:  2013-10-21       Impact factor: 11.151

5.  Deliberately provoking local inflammation drives tumors to become their own protective vaccine site.

Authors:  Connie Jackaman; Andrew M Lew; Yifan Zhan; Jane E Allan; Biljana Koloska; Peter T Graham; Bruce W S Robinson; Delia J Nelson
Journal:  Int Immunol       Date:  2008-09-29       Impact factor: 4.823

Review 6.  Oncology meets immunology: the cancer-immunity cycle.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

7.  Intratumoral immunization: a new paradigm for cancer therapy.

Authors:  Aurélien Marabelle; Holbrook Kohrt; Christophe Caux; Ronald Levy
Journal:  Clin Cancer Res       Date:  2014-04-01       Impact factor: 12.531

Review 8.  Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies.

Authors:  Andrew J S Furness; Frederick Arce Vargas; Karl S Peggs; Sergio A Quezada
Journal:  Trends Immunol       Date:  2014-06-18       Impact factor: 16.687

9.  Agonistic CD40 antibodies and cancer therapy.

Authors:  Robert H Vonderheide; Martin J Glennie
Journal:  Clin Cancer Res       Date:  2013-03-01       Impact factor: 12.531

Review 10.  Immune modulation for cancer therapy.

Authors:  J Naidoo; D B Page; J D Wolchok
Journal:  Br J Cancer       Date:  2014-09-11       Impact factor: 7.640
  10 in total
  7 in total

Review 1.  HIV-specific CD8⁺ T cells and HIV eradication.

Authors:  R Brad Jones; Bruce D Walker
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

Review 2.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors:  Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110

Review 3.  Phosphoinositide 3-kinase/Akt and its related signaling pathways in the regulation of tumor-associated macrophages polarization.

Authors:  Depeng Yang; Lijun Yang; Jialing Cai; Huaxin Li; Zheng Xing; Ying Hou
Journal:  Mol Cell Biochem       Date:  2022-05-19       Impact factor: 3.842

Review 4.  New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.

Authors:  Isabel Corraliza-Gorjón; Beatriz Somovilla-Crespo; Silvia Santamaria; Jose A Garcia-Sanz; Leonor Kremer
Journal:  Front Immunol       Date:  2017-12-21       Impact factor: 7.561

Review 5.  Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation.

Authors:  Peter Ellmark; Sara M Mangsbo; Christina Furebring; Per Norlén; Thomas H Tötterman
Journal:  Cancer Immunol Immunother       Date:  2016-10-06       Impact factor: 6.968

Review 6.  Symphony of nanomaterials and immunotherapy based on the cancer-immunity cycle.

Authors:  Qianqian Li; Zhaoqing Shi; Fan Zhang; Weiwei Zeng; Dunwan Zhu; Lin Mei
Journal:  Acta Pharm Sin B       Date:  2021-06-02       Impact factor: 11.413

Review 7.  Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles.

Authors:  Angelica Loskog
Journal:  Viruses       Date:  2015-11-06       Impact factor: 5.048
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.